Zhaoke Ophthalmology Pharmaceutical (ZKO), an indirect subsidiary of Hong Kong-listed Lee’s Pharmaceutical Holdings Limited, has garnered as much as $145 million in its Series B round co-led by Hillhouse Capital’s Hillhouse COFL and TPG Asia, per a filing with the Stock Exchange of Hong Kong (HKEx) on October 11.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in